Can-Fite BioPharma (NYSE:CANF) Given Buy Rating at D. Boral Capital

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 476.37% from the company’s current price.

Separately, StockNews.com initiated coverage on shares of Can-Fite BioPharma in a research report on Saturday. They set a “sell” rating for the company.

Can-Fite BioPharma Stock Performance

Shares of CANF stock traded up $0.09 on Tuesday, hitting $1.74. The company’s stock had a trading volume of 1,537,110 shares, compared to its average volume of 181,582. The stock’s 50 day moving average is $1.58 and its 200-day moving average is $1.88. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The company has a market capitalization of $6.14 million, a PE ratio of -0.97 and a beta of 1.12.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.